Literature DB >> 12495970

Is there a role for treatment of asthma with omalizumab?

H Milgrom1.   

Abstract

The allergic response is distinct from other immune reactions in its reliance on IgE, its high affinity receptor, Fc epsilon RI, and the primary effector cell--the tissue mast cell. Positive skin tests or raised concentrations of specific immunoglobulin E (IgE) in the serum define IgE sensitisation or "atopy". IgE participates both in immediate hypersensitivity response and in the induction of chronic allergic inflammation. It enhances allergen capture and Th2 cell activation, and may trigger other immunoregulatory pathways. Considerable effort in therapeutic research has focused on interference with IgE function because of its position high in the allergic cascade. Therapy with anti-IgE is one such approach that shows much promise.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12495970      PMCID: PMC1719268          DOI: 10.1136/adc.88.1.71

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  48 in total

Review 1.  The pharmacological basis of anti-IgE therapy.

Authors:  T W Chang
Journal:  Nat Biotechnol       Date:  2000-02       Impact factor: 54.908

Review 2.  Asthma.

Authors:  W W Busse; R F Lemanske
Journal:  N Engl J Med       Date:  2001-02-01       Impact factor: 91.245

3.  Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis.

Authors:  E Adelroth; S Rak; T Haahtela; G Aasand; L Rosenhall; O Zetterstrom; A Byrne; K Champain; J Thirlwell; G D Cioppa; T Sandström
Journal:  J Allergy Clin Immunol       Date:  2000-08       Impact factor: 10.793

Review 4.  Prevention of adult asthma by early intervention during childhood: potential value of new generation immunomodulatory drugs.

Authors:  P G Holt; P D Sly
Journal:  Thorax       Date:  2000-08       Impact factor: 9.139

5.  Asthma in preschool children: prevalence and risk factors.

Authors:  M M Haby; J K Peat; G B Marks; A J Woolcock; S R Leeder
Journal:  Thorax       Date:  2001-08       Impact factor: 9.139

6.  Decreases in asthma mortality in the United States.

Authors:  R M Sly
Journal:  Ann Allergy Asthma Immunol       Date:  2000-08       Impact factor: 6.347

7.  Invited lecture: activation of the epithelial mesenchymal trophic unit in the pathogenesis of asthma.

Authors:  S T Holgate; P M Lackie; P H Howarth; W R Roche; S M Puddicombe; A Richter; S J Wilson; J W Holloway; D E Davies
Journal:  Int Arch Allergy Immunol       Date:  2001 Jan-Mar       Impact factor: 2.749

8.  Nonreversible airflow obstruction in life-long nonsmokers with moderate to severe asthma.

Authors:  C S Ulrik; V Backer
Journal:  Eur Respir J       Date:  1999-10       Impact factor: 16.671

Review 9.  Allergy and allergic diseases. First of two parts.

Authors:  A B Kay
Journal:  N Engl J Med       Date:  2001-01-04       Impact factor: 91.245

Review 10.  Present and future treatment of asthma in infants and young children.

Authors:  F D Martinez
Journal:  J Allergy Clin Immunol       Date:  1999-10       Impact factor: 10.793

View more
  3 in total

Review 1.  Immunotherapy in the age of anti-IgE.

Authors:  Ira Finegold
Journal:  Clin Rev Allergy Immunol       Date:  2004-10       Impact factor: 8.667

Review 2.  Omalizumab: a monoclonal anti-IgE antibody.

Authors:  Paul P Belliveau
Journal:  MedGenMed       Date:  2005-01-27

Review 3.  Ethical considerations in research involving children.

Authors:  Theresa A O'Lonergan; Henry Milgrom
Journal:  Curr Allergy Asthma Rep       Date:  2005-11       Impact factor: 4.919

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.